Plus Therapeutics, Inc. (NASDAQ: PSTV) reported Q3 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Plus Therapeutics, Inc. (PSTV) click here.